Kathleen Berth

Verve Therapeutics, Cambridge, MA, USA.

1 publication 2021 – 2021
Gene EditingCRISPR-Cas SystemsCells, CulturedAdenineCholesterol, LDL

What does Kathleen Berth research?

Dr. Kathleen Berth studies how gene editing can be used to manage cholesterol levels in the body. One of her main research tools is called CRISPR, which allows scientists to modify genes in a precise way. In her work, she specifically targets the PCSK9 gene, which plays a key role in cholesterol production. By using CRISPR to disable this gene in primates, she has demonstrated a significant drop in cholesterol levels, suggesting a potential breakthrough for patients who struggle with high cholesterol and the long-term use of medications.

Key findings

  • A single injection using CRISPR base editing led to a 60% reduction in cholesterol levels in monkeys.
  • The low cholesterol levels were maintained for at least 8 months without any further treatment.
  • This research indicates that gene editing could offer a one-time treatment option for heart disease patients.

Frequently asked questions

Does Dr. Berth study high cholesterol?
Yes, she focuses on using gene editing to lower cholesterol levels.
What is CRISPR and how is it used in Dr. Berth's research?
CRISPR is a gene-editing tool that allows scientists to make precise changes to DNA, and Dr. Berth uses it to disable genes that influence cholesterol production.
Is Dr. Berth's work relevant to heart disease patients?
Absolutely, her research aims to provide long-lasting cholesterol control which is crucial for managing heart disease.

Publications in plain English

In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.

2021

Nature

Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE +37 more

Plain English
Researchers used a gene-editing tool called CRISPR to permanently disable a gene in monkeys' livers that controls cholesterol production, delivering it through tiny fat particles injected into the bloodstream. After a single injection, the monkeys' cholesterol dropped by about 60% and stayed low for at least 8 months without any additional treatment. This proves that gene editing could offer heart disease patients a one-time treatment instead of taking cholesterol drugs for life.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.